According to Altmetric, which tracks the distribution and discussion of research papers online, a July article by several Yale physicians is the most-discussed paper ever published in the Journal of the National Cancer Institute (JNCI). The title of this blockbuster: “Use of Alternative Medicine for Cancer and Its Impact on Survival.”
New research by Yale Cancer Center (YCC) researchers shows a majority of pediatric cancer providers endorse the potential use of medical marijuana for children with advanced cancer, although providers who are legally eligible to certify its use are more cautious than those who aren’t.
With November Lung Cancer Awareness Month, experts from Yale Cancer Center talk about lung cancer screening and why it is can save lives.
For some cancer patients, the road to remission and healing can have its share of speed bumps. That’s particularly true of patients with non-small cell lung cancer (NSCLC) who develop a secondary, or acquired, resistance to immunotherapy, which initially was effective against their tumors.
Dr. Rogerio Lilenbaum, a board member of NCCN and Chief Medical Officer of Smilow Cancer Hospital at the Yale Cancer Center said that for nonsmall-cell lung cancer, both panel testing and liquid biopsies are appropriate.
Yale Cancer Center scientists now have made a fundamental discovery about EGFR signaling, reported in the journal Cell, that may open the potential for new types of cancer drugs.
It's been 20 years since the BRCA1 gene was found to predispose women to breast cancer, and researchers at Yale have pinpointed what about the gene's mutation leads to cancer.
More than 20 years after scientists revealed that mutations in the BRCA1 gene predispose women to breast cancer, Yale scientists have pinpointed the molecular mechanism that allows those mutations to wreak their havoc.
With October marking National Breast Cancer Awareness month, a breast cancer expert at Yale Cancer Center, sorts out the facts about breast cancer and offers simple ways to reduce risk.
There is an increased risk of thyroid cancer associated with lower-than-normal thyroid hormone levels, a finding that could have a major impact on patients fighting the disease.
Tumor-destroying vaccines have emerged as a new weapon in the fight against cancer.
Older, terminally ill patients could improve the quality of their last days by accessing hospice services much sooner, according to a Yale School of Medicine-led study.
A multigene panel test could be a useful diagnostic tool to help clinicians identify patients with a hereditary kidney cancer syndrome, according to the results of a study published in Cancer.
Not all kidney cancers are killers, and many small tumors can be left alone or watched over time because there is a low risk they will become dangerous, according to Dr. Brian Shuch at the Yale School of Medicine.
Ramucirumab plus docetaxel improves progression-free survival in patients with advanced or metastatic urothelial cancer who have progressed on platinum-based chemotherapy, according to late-breaking results from the phase III RANGE trial presented today at the ESMO 2017 Congress in Madrid (1) to be published in The Lancet (2).
The National Cancer Institute (NCI) has named Peter M. Glazer, M.D., Ph.D., as a recipient of its Outstanding Investigator Award (OIA).
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right